121 related articles for article (PubMed ID: 8786983)
1. Absorption of an oxytocin antagonist (antocin) and a vasopressin analogue (dDAVP) through a standardized skin erosion in volunteers.
Lundin S; Svedman P; Höglund P; Jönsson K; Broeders A; Melin P
Pharm Res; 1995 Dec; 12(12):2024-9. PubMed ID: 8786983
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of vasopressin, oxytocin and their analogues [Mpa1, D-Arg8]-vasopressin (dDAVP) and [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in human kidney and liver homogenates.
Fjellestad-Paulsen A; Lundin S
Regul Pept; 1996 Nov; 67(1):27-32. PubMed ID: 8952002
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers.
Lundin S; Broeders A; Melin P
Clin Endocrinol (Oxf); 1993 Sep; 39(3):369-74. PubMed ID: 8222299
[TBL] [Abstract][Full Text] [Related]
4. Differences in transport rate of oxytocin and vasopressin analogues across proximal and distal isolated segments of the small intestine of the rat.
Lundin S; Pantzar N; Broeders A; Ohlin M; Weström BR
Pharm Res; 1991 Oct; 8(10):1274-80. PubMed ID: 1796046
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal absorption and plasma clearance rates of [D-Arg8]vasopressin analogues in the rat.
Lundin S; Folkesson HG; Pierzynovski SG; Bengtsson HI
Peptides; 1994; 15(5):809-14. PubMed ID: 7984498
[TBL] [Abstract][Full Text] [Related]
6. V2-like vasopressin receptor mobilizes intracellular Ca2+ in rat medullary collecting tubules.
Champigneulle A; Siga E; Vassent G; Imbert-Teboul M
Am J Physiol; 1993 Jul; 265(1 Pt 2):F35-45. PubMed ID: 8342613
[TBL] [Abstract][Full Text] [Related]
7. Antagonists for the human oxytocin receptor: an in vitro study.
Maggi M; Fantoni G; Baldi E; Cioni A; Rossi S; Vannelli GB; Melin P; Akerlund M; Serio M
J Reprod Fertil; 1994 Jul; 101(2):345-52. PubMed ID: 7932368
[TBL] [Abstract][Full Text] [Related]
8. Administration of antidiuretic peptide (DDAVP) by way of suction de-epithelialised skin.
Svedman P; Lundin S; Svedman C
Lancet; 1991 Jun; 337(8756):1506-9. PubMed ID: 1675370
[TBL] [Abstract][Full Text] [Related]
9. Enhancing effects of monohexanoin and two other medium-chain glyceride vehicles on intestinal absorption of desmopressin (dDAVP).
Lundin PD; Bojrup M; Ljusberg-Wahren H; Weström BR; Lundin S
J Pharmacol Exp Ther; 1997 Aug; 282(2):585-90. PubMed ID: 9262318
[TBL] [Abstract][Full Text] [Related]
10. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
11. Degradation of [mercaptopropionic acid1, D-arginine8]-vasopressin (dDAVP) in pancreatic juice and intestinal mucosa homogenate.
Lundin S; Bengtsson HI; Folkesson HG; Weström BR
Pharmacol Toxicol; 1989 Aug; 65(2):92-5. PubMed ID: 2813288
[TBL] [Abstract][Full Text] [Related]
12. Use of three specific radioimmunoassays in measuring neurohypophysial hormone content and plasma concentrations of vasopressin, oxytocin and DDAVP in rats after prolonged infusion of DDAVP.
Lundin S; Melin P; Vilhardt H
Experientia; 1985 Jul; 41(7):933-5. PubMed ID: 4007132
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of vasopressin, oxytocin, and their analogues in the human gastrointestinal tract.
Fjellestad-Paulsen A; Söderberg-Ahlm C; Lundin S
Peptides; 1995; 16(6):1141-7. PubMed ID: 8532599
[TBL] [Abstract][Full Text] [Related]
14. Biliary excretion of the vasopressin analogue DDAVP after intraduodenal, intrajugular and intraportal administration in the conscious pig.
Lundin S; Pierzynovski SG; Weström BR; Bengtsson HI
Pharmacol Toxicol; 1991 Mar; 68(3):177-80. PubMed ID: 2057448
[TBL] [Abstract][Full Text] [Related]
15. The effects of [Arg8]vasopressin and [Arg8]vasotocin on the firing rate of suprachiasmatic neurons in vitro.
Mihai R; Coculescu M; Wakerley JB; Ingram CD
Neuroscience; 1994 Oct; 62(3):783-92. PubMed ID: 7870306
[TBL] [Abstract][Full Text] [Related]
16. Proconvulsive effect of vasopressin; mediation by a putative V2 receptor subtype in the central nervous system.
Croiset G; De Wied D
Brain Res; 1997 Jun; 759(1):18-23. PubMed ID: 9219858
[TBL] [Abstract][Full Text] [Related]
17. Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).
Yamaguchi Y; Yamada K; Suzuki T; Wu YP; Kita K; Takahashi S; Ichinose M; Suzuki N
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E970-6. PubMed ID: 15198931
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers.
Fjellestad-Paulsen A; d'Agay-Abensour L; Höglund P; Rambaud JC
Eur J Clin Pharmacol; 1996; 50(6):491-5. PubMed ID: 8858277
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers.
Fjellestad-Paulsen A; Höglund P; Lundin S; Paulsen O
Clin Endocrinol (Oxf); 1993 Feb; 38(2):177-82. PubMed ID: 8435898
[TBL] [Abstract][Full Text] [Related]
20. Effect of the oxytocin antagonist antocin and agonist decomoton on baboon luteal cell production and release of progesterone.
Dawood MY; Khan-Dawood FS
Fertil Steril; 2008 Oct; 90(4 Suppl):1366-71. PubMed ID: 18054931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
